lurbinectedin sold brand name zepzelca medication used treatment small cell lung common side effects include leukopenia lymphopenia fatigue anemia neutropenia increased creatinine increased alanine aminotransferase increased glucose thrombocytopenia nausea decreased appetite musculoskeletal pain decreased albumin constipation dyspnea decreased sodium increased aspartate aminotransferase vomiting cough decreased magnesium lurbinectedin synthetic tetrahydropyrrolo alkaloid analogue potential antineoplastic lurbinectedin covalently binds residues lying minor groove dna may result delayed progression phase cell cycle arrest phase cell lurbinectedin approved medical use united states june lurbinectedin indicated treatment adults metastatic small cell lung cancer sclc disease progression platinumbased lurbinectedin structurally similar trabectedin although tetrahydroisoquinoline present trabectedin replaced tetrahydro Î²carboline enables lurbinectedin exhibit increased antitumor activity compared synthesis lurbinectedin starts small common starting materials require twentysix individual steps produce drug overall yield according lurbinectedin inhibits active transcription encoding genes two consequences promotes tumor cell death normalizes tumor microenvironment active transcription process specific signal information contained dna sequence transferred rna molecule activity depends activity enzyme called rna polymerase ii lurbinectedin inhibits transcription precise mechanism firstly lurbinectedin binds specific dna sequences precise spots slides dna produce rna polymerase ii blocked degraded lurbinectedin lurbinectedin also important role tumor microenvironment tumor cells act upon macrophages avoid behaving like activator immune system macrophages contribute tumor growth progression promoting tumor cell proliferation invasion fostering tumor angiogenesis suppressing antitumor immune attracted oxygenstarved hypoxic necrotic tumor cells promote chronic inflammation macrophages inhibit immune system avoiding destruction tumor cells also create tumor tissue allows tumor growth however macrophages associated tumors cells addicted transcription process lurbinectedin acts specifically macrophages associated tumors two ways firstly inhibiting transcription macrophages leads cell death secondly inhibiting production tumor growth factors way lurbinectedin normalizes tumor microenvironment lurbinectedin approved medical use united states june efficacy demonstrated trial study multicenter openlabel multicohort study enrolling participants metastatic sclc disease progression platinumbased participants received lurbinectedin intravenous infusion every days disease progression unacceptable trial conducted sites united states great britain belgium france italy spain czech us food drug administration fda granted application lurbinectedin priority review orphan drug designations granted approval zepzelca pharma mar lurbinectedin used monotherapy treatment sclcmedical citation needed lurbinectedin monotherapy demonstrated following clinical results relapsed extensive stage sclc lurbinectedin also investigated combination doxorubicin secondline therapy randomized phase iii trialmedical citation needed overall survival trial yet known response rates second line lurbinectedin available us expanded access program httpsenwikipediaorgwikilurbinectedin